Drug intelligence / Profile preview

XNTR-936

Development stage: Preclinical
Lead developer: Xennials Therapeutics
Modality: Small Molecules

Overview

XNTR-936 is a preclinical-stage investigational drug being developed by Xennials Therapeutics. It is a multi-targeted therapeutic construct designed to inhibit Signal Transducer and Activator of Transcription (STAT), the Androgen Receptor N-terminal domain (AR NTD), and Poly ADP Ribose Polymerase (PARP). This multi-pronged approach is intended to disrupt key survival and DNA repair pathways in cancer cells, specifically targeting metastatic hormone-sensitive prostate cancer (mHSPC) and triple-negative breast cancer (TNBC). The drug is part of a pipeline of inhibitors aimed at addressing unmet needs in oncology through the simultaneous modulation of multiple oncogenic drivers.

Targets

AR (Adrenergic receptors)PARP (PARP family)STAT (STAT family)

Beyond the preview

Go deeper on XNTR-936.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XNTR-936.

Explore the full profile